Tag Archives: ATRA

Best Small Cap Stocks To Own Right Now

Today, our Under the Radar Movers newsletter suggested shorting small cap optical solutions manufacturing stock LightPath Technologies (NASDAQ: LPTH) in our short term portfolio:

“Lightpath just squandered its best shot at a rebound on Friday, with a high-volume surge that petered out with a mere brush of the 20-day moving average line (blue)…. a resistance line that’s been a problem other times in the recent past. The sellers jumped on again, rekindling a downtrend that’s been firmly in place since late September.”

“It probably won’t be a red-hot downtrend, but slow and steady wins the race.”

Our Under the Radar Movers newsletter has a further discussion about LightPath Technologies’ technical chart along with a shorting strategy:

Best Small Cap Stocks To Own Right Now: The ExOne Company(XONE)

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    The ExOne Company (NASDAQ:XONE)Q2 2018 Earnings Conference CallAug. 10, 2018, 8:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Paul Ausick]

    Short interest in The ExOne Co. (NASDAQ: XONE) jumped 21.2% to 2.88 million shares. About 29.6% of the company’s shares were short. ExOne’s share price fell by about 5.6% in the two weeks ending May 15. The stock’s 52-week range is $6.23 to $14.23, and shares closed at $6.33 on Thursday, down about 0.2% for the day. Days to cover fell from 23 to 15.

  • [By Logan Wallace]

    Shares of ExOne Co (NASDAQ:XONE) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $13.67.

  • [By Paul Ausick]

    Short interest in ExOne Co. (NASDAQ: XONE) fell by 9.9% to 2.33 million shares. About 24% of the company’s shares were short. ExOne’s share price soared by nearly 24% in the period ending August 31. The stock’s 52-week range is $6.16 to $12.50, and shares closed at $8.93 on Wednesday, up about 4.8% for the day. Days to cover rose from 10 to 16.

  • [By Paul Ausick]

    Short interest in The ExOne Co. (NASDAQ: XONE) rose by 4.9% to 2.38 million shares. About 24.4% of the company’s shares were short. ExOne’s share price fell by about 3.4% in the period ending April 30. The stock’s 52-week range is $6.72 to $14.43, and shares closed at $7.19 on Wednesday, up about 2.7% for the day. Days to cover rose from 22 to 23.

  • [By Paul Ausick]

    Short interest in ExOne Co. (NASDAQ: XONE) fell by 3.9% to 2.75 million shares. About 28.2% of the company’s shares were short. ExOne’s share price rose by about 4.7% in the short interest period. The stock’s 52-week range is $6.16 to $12.50, and shares closed at $7.22 on Wednesday, down about 3.6% for the day. Days to cover fell from 17 to seven.

Best Small Cap Stocks To Own Right Now: Optibase Ltd.(OBAS)

Advisors’ Opinion:

  • [By Max Byerly]

    News headlines about Optibase (NASDAQ:OBAS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Optibase earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the financial services provider an impact score of 45.6853785900783 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Best Small Cap Stocks To Own Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Rhumbline Advisers boosted its position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 23.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 33,565 shares of the biotechnology company’s stock after purchasing an additional 6,363 shares during the quarter. Rhumbline Advisers’ holdings in Atara Biotherapeutics were worth $1,309,000 at the end of the most recent reporting period.

  • [By Danny Vena, George Budwell, and Daniel Miller]

    With that in mind, we asked three Motley Fool contributors to identify growth stocks with intriguing potential that might not be on the radar of most investors. They picked Shopify Inc. (NYSE:SHOP), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), and Criteo S.A. (NASDAQ:CRTO).

  • [By Jason Hall, George Budwell, and Chuck Saletta]

    In order to help you get started, we asked three real-world investors who also write for The Motley Fool to put forth their best “buy now” growth stock ideas, and they came up with high-growth home builder LGI Homes Inc (NASDAQ:LGIH), return-to-growth restaurant chain Chipotle Mexican Grill, Inc. (NYSE:CMG), and upstart immunotherapy developer Atara BioTherapeutics Inc (NASDAQ:ATRA). 

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) Director Matthew K. Fust sold 12,286 shares of Atara Biotherapeutics stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $43.57, for a total value of $535,301.02. Following the completion of the transaction, the director now directly owns 19,820 shares of the company’s stock, valued at approximately $863,557.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top Medical Stocks To Watch For 2018

Canadian Prime Minister Justin Trudeau promised he would implement massive changes to Canada marijuana laws. And when he does, it will create a new and booming economy.

If Canada places a “sin tax” of 50% on recreational marijuana sales, the country could make $5 billion annually, according to a CIBC World Markets report.

Currently, only medical marijuana is legal in Canada.

But an overwhelming amount of Canadians support legalizing recreational marijuana…

According to a poll conducted in the summer of 2016, 43% of the 1,000 Canadians surveyed supported legalizing recreational marijuana. Also, 26% of those surveyed somewhat supported legalizing recreational marijuana.

Only 17% were opposed, and 9% were somewhat opposed.

Top Medical Stocks To Watch For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Atara Biotherapeutics (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,800 shares of the business’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $39.85, for a total transaction of $350,680.00. Following the sale, the chief executive officer now owns 812,613 shares of the company’s stock, valued at $32,382,628.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

  • [By Ethan Ryder]

    Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13), MarketWatch Earnings reports.

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

  • [By Danny Vena, George Budwell, and Daniel Miller]

    With that in mind, we asked three Motley Fool contributors to identify growth stocks with intriguing potential that might not be on the radar of most investors. They pickedShopify Inc. (NYSE:SHOP), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), and Criteo S.A. (NASDAQ:CRTO).

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) Director Matthew K. Fust sold 12,286 shares of Atara Biotherapeutics stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $43.57, for a total value of $535,301.02. Following the completion of the transaction, the director now directly owns 19,820 shares of the company’s stock, valued at approximately $863,557.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

  • [By Max Byerly]

    Atara Biotherapeutics (NASDAQ:ATRA) SVP Derrell Porter sold 1,544 shares of the firm’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $40.15, for a total value of $61,991.60. Following the completion of the sale, the senior vice president now owns 12,500 shares in the company, valued at $501,875. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Top Medical Stocks To Watch For 2018: Sanofi(SNY)

Advisors’ Opinion:

  • [By Max Byerly]

    COPYRIGHT VIOLATION NOTICE: “Sanofi (SNY) Stock Rating Reaffirmed by Deutsche Bank” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3361890/sanofi-sny-stock-rating-reaffirmed-by-deutsche-bank.html.

  • [By Cory Renauer]

    We didn’t need to wait for Regeneron’s first-quarter earnings report to know how well its drugs are performing. Analysts had already started fretting over Dupixent sales, which reached just$128 million in the first quarter, according to the biotech’s collaboration partnerSanofi (NYSE:SNY).

  • [By Cory Renauer]

    Sanofi (NYSE:SNY) andRegeneron (NASDAQ:REGN) launched a cholesterol-lowering treatment in 2015 that could be a big problem for bempedoic acid, even if its safety profile remains intact. Praluent is a remarkable drug that can turn stubborn liver cells into cholesterol sponges, but at an initial list price of around $14,000 per year, its launch was a huge disappointment.

Top Medical Stocks To Watch For 2018: Cellect Biotechnology Ltd. (APOP)

Advisors’ Opinion:

  • [By Shane Hupp]

    Cellect Biotechnology (NASDAQ: APOP) is one of 105 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Cellect Biotechnology to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

  • [By Lisa Levin] Gainers
    Pacific Biosciences of California, Inc. (NASDAQ: PACB) rose 11.4 percent to $2.93 in pre-market trading.
    Check-Cap Ltd. (NASDAQ: CHEK) shares rose 6.3 percent to $4.76 in pre-market trading as the company announced the publication of CE Mark multicenter clinical study results on C-Scan® in Gut.
    Acacia Communications, Inc. (NASDAQ: ACIA) rose 6 percent to $ 35.20 in pre-market trading.
    Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 6 percent to $7.60 in pre-market trading.
    Hexindai Inc. (NASDAQ: HX) rose 5.7 percent to $12.70 in pre-market trading.
    MoSys, Inc. (NASDAQ: MOSY) shares rose 5.3 percent to $2.07 in pre-market trading.
    Micron Technology, Inc. (NASDAQ: MU) rose 5 percent to $58.20 in pre-market trading after reporting a $10 billion buyback plan.
    Golden Ocean Group Limited (NASDAQ: GOGL) rose 4.1 percent to $8.63 in pre-market trading.
    MorphoSys AG (NASDAQ: MOR) rose 3.5 percent to $26.99 in pre-market trading.
    Cyren Ltd (NASDAQ: CYRN) shares rose 3.4 percent to $2.90 in pre-market trading. after reporting Q1 results.
    Box, Inc. (NYSE: BOX) rose 3.4 percent to $28.76 in pre-market trading.
    Kohl's Corporation (NYSE: KSS) shares rose 3.3 percent to $67.60 in the pre-market trading session after the company reported upbeat quarterly earnings.
    Micro Focus International plc (NYSE: MFGP) shares rose 3.1 percent to $18.40 in pre-market trading.

     

Top Medical Stocks To Watch For 2018: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By ]

    Nu Skin Enterprises (NYSE: NUS) is benefiting from two key trends: its strong presence in Asia where it books 79% of its revenue and leading brand awareness with millennials. The company has increased its dividend every year since 2001, now paying a 2% yield, and maintains a share repurchase program that returns excess cash to shareholders.

Top Medical Stocks To Watch For 2018: United Insurance Holdings Corp.(UIHC)

Advisors’ Opinion:

  • [By Shane Hupp]

    United Insurance (NASDAQ:UIHC) announced its quarterly earnings results on Tuesday. The insurance provider reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.02, Bloomberg Earnings reports. United Insurance had a return on equity of 9.16% and a net margin of 2.05%. The company had revenue of $182.36 million during the quarter, compared to analyst estimates of $178.33 million.

TG Therapeutics: Assessing The Investment Prospects Of A Potential Big Winner

TG Therapeutics (NASDAQ:TGTX) is an interesting bioscience that is approaching its growth inflection that is binary (i.e., a make or break catalytic event). There is a good chance that years of efforts in brewing a promising pipeline of potential blockbusters are about to pay off with the upcoming data reporting for the phase 3 (UNITY-CLL) trial. If positive, there is substantial value to be unlocked in this investment. Despite the strong fundamentals, the stock has been trading only slightly higher in the past 52 weeks. Notably, the shares exchanged hands up by $1.35 at $13.10 for the meager 11%+ gains. In this research, well elucidate the underlying fundamentals of TG Therapeutics, while focusing on the upcoming binary catalyst that can catapult the valuation to a new high.

Figure 1: TG Therapeutics stock chart (Source: StockCharts)

Fundamental Analysis

Headquartered in New York City, TG Therapeutics is focusing on the innovation and commercialization of differentiated molecules to service B-cell cancers and autoimmune diseases. As depicted in figure 2, there are two late-stage franchises. The first is ublituximab (TG-1101), a novel antibody targeting the unique epitope on the CD20 marker found on B-lymphocytes. Second is umbralisib (TGR-1202), an oral formulation of a PI3K delta inhibitor for different blood malignancies. As follows, the delta isoform of PI3K is abundant in blood cancer cells like B-lymphocytes: it is believed to have key roles in survival and multiplication. Hence, the targeting of PI3K is quite prudent against these rogue cells.

Despite the fact that other pipeline prospects can deliver strong clinical outcomes, we are most interested in the combination of umbrasilib with ublituximab (U2). Investigating in the phase 3 (UNITY-CLL and UNITY-NHL) trials, U2 is being assessed for its efficacy and safety in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), respectively.

Figure 2: Therapeutic pipeline (Source: TG Therapeutics)

In addition, the company is assessing the prospects of ublituximab in patients afflicted by multiple sclerosis (MS). Regardless of the potential positive data for the MS franchise, the targeting of the immune system by knocking it down as with immunosuppressive therapies is an acceptable approach. And yet, it lacks the novelty and safety variables that we are seeking. Contrarily, were thrilled by the ingenious strategy employed by ATA-188 of Atara Biotherapeutics (NASDAQ:ATRA), which prevents the MS flare-ups rather than attacking the immune system. Ultimately, this novel approach should deliver excellent safety and superior tolerability.

For Q1 2018 (ended on March 31), TG Therapeutics posted net losses of $41.5 million, compared to a $27.7 million net decline for the same period a year prior. On the balance sheet, there are $109.2 million, compared to the $123.3 million for the similar period. During Q2, the company raised $14.1 million from the public offering. Based on the $28.0 million quarterly burn rate, there should be adequate capital to fund operations through mid-2019 (prior to any additional financing). Investors should be cognizant that it is the norm for a relatively young bioscience like TG Therapeutics to incur significant losses for many years prior to banking a net profit (due to the lengthy and low success rate of the innovation process). Nonetheless, it only takes one blockbuster to make your investment worthwhile.

While there are a good number of events to stimulate further growth, the upcoming phase 3 (UNITY-CLL) trial – studying U2 in the front line and relapse as well as refractory CLL – is the most important. Notably, TG Therapeutics will present the top line overall response rate sometime later this year. With the trial completion expected in November 2018, we expect the data to be promptly reported thereafter. Commenting on the recent development, Chairman and CEO Michael Weiss enthused:

2018 is off to a great start as we continue to advance our major pivotal programs and bolster our product pipeline, most recently with the addition of a BTK inhibitor. As we move into the second quarter and the remainder of the year, we look forward to the announcement of topline data from our UNITY-CLL trial, completion of enrollment into the current cohorts of the UNITY-NHL study, final MS phase 2 data, significant enrollment in our MS phase 3 program as well as filing decisions related to the companys first BLA/NDA later in the year. We believe 2018 will be a pivotal year for the company as approval pathways across multiple indications become clearer and position us for future success.

Final Remark

TG Therapeutics is brewing a pipeline of highly promising drugs. With key catalysts powering its growth, the firm can be a lucrative investment. The U2 program has a good chance of delivering positive endpoints. In the case of a favorable binary, it is not far from the truth that the stock can appreciate over 70% from its current valuation (and vice-versa). If excellent outcomes are posted, U2 can tap into the lucrative multi-billion dollar market (and to service most prevalent conditions). The relative novelty and the prudent combinations of U2 enabled it to highly likely gain a significant market share. Additionally, the financials and valuations are also favorable. Last but not least, the company can be a target of acquisition in the current merger & acquisition conducive environment. Risk-wise, the main concern is if U2 can post positive outcomes. Given that the company is heavily dependent on this upcoming catalyst, its most likely that the share price can move over 70% in either direction (pending UNITY-CLL results).

Authors Notes: Were honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (IBI) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 320%, 160%, 242%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advanced and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I like to inform our readers of Seeking Alpha’s recent policy change, in which the company implemented the paywall (not only to my articles, but to all articles that are published over 10 days ago). This is in place as the company is, after all, a business. And the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL-TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.

Rounds Report: Omeros Rallied While Stellar FDA Due Diligence To Help Atara Biotherapeutics

You need a different checklist and different mental models for different companies. I can never make it easy by saying, Here are three things. You have to derive it yourself to ingrain it in your head for the rest of your life. – Charlie Munger

Trading Analytics

Welcome to this edition of Integrated BioSci Rounds Report for May 11, 2018. As usual, well elucidate notable trading analytics for the day, recent insider transactions, and interesting market developments. Without further ado, lets take an overall assessment of the bioscience space. As follows, the iShares of NASDAQ Biotechnology Index (NASDAQ:IBB) traded up by $2.85 (+2.75%) at $106.58. Moreover, the SPDR S&P Biotech (NASDAQ:XBI) exchanged hands $2.61 higher at $91.65 (for +2.93% gains). Its likely that investors were trading with a resurged sense of optimism to close out the week with an exclamation mark. Regardless of the daily inclination, there are substantial prospects in the bioscience sector: one that delivers hope for patients while rewarding supporters with substantial wealth in the long haul.

Figure 1: Notable BioSci movers. (Source: Morningstar)

Moving to specific equities, Omeros Corporation (NASDAQ:OMER) won the highlight spot of the day. The stock traded $3.76 higher at $19.89 (for 23.31% profits). Headquartered in Seattle WA, Omeros focused on the therapeutic innovation and commercialization to service inflammation, complement-mediated diseases, and central nervous system disorder (as depicted in figure 2). Already approved, Omidria is utilized to maintain the pupil size during cataract surgery and to reduce postoperative pain.


Figure 2: Therapeutic pipeline (Source: Omeros)

Today, the company reported strong earnings for Q1 2018. Notably, Omidria is providing the cash to fund further medicinal development. And, OMS-721 (the crown jewel of the pipeline) is progressing as anticipated: the miracle drug is most likely to gain an accelerated approval and ultimately to become a powerful blockbuster.

Bioscience Catalysts

On May 11, the FDA approved the use of Novartis (NYSE:NVS)s fingolimod (Gilenya) for the treatment of relapsing multiple sclerosis (MS) in children and adolescents 10 years or older. Already commercialized to treat adults with MS, Gilenya is now available for kids and teens for the first time. Commenting on the latest development, the FDA Director of Neurology (Dr. Billy Dunn) enthused,

For the first time, we have an FDA-approved treatment specifically for children and adolescents with multiple sclerosis. Multiple sclerosis can have a profound impact on a childs life. This approval represents an important and needed advance in the care of pediatric patients with multiple sclerosis.

The aforementioned catalyst provides another life-saving treatment option for these patients (as MS is a deadly disease). Despite that the therapeutic benefits far outweigh the harms, there are significant adverse effects. Of note, Gilenya and other MS drugs week to suppress the immune system by attacking key immune components, thereby leading to significant adverse effects. In contrast, Atara Biotherapeutics (NASDAQ:ATRA) is innovating a stellar molecule (ATA-188) that can circumvent the said limitations. Interestingly, ATA-188 takes a completely different approach toward MS treatment. The molecule is powering a unique and novel mechanism of action not seen thus far. Rather than attacking the immune system (which causes significant adverse effects), ATA-188 suppresses the viral elements that, in and of itself, incite the immune system to flare up in the first place. With the said industrial tailwind, Atara is most likely to experience the robust value appreciation (if it can demonstrate strong clinical outcomes for ATA-188 as we prognosticated).

Final Remarks

In all, the bioscience market enjoyed a strong rally for the day. Many equities under our coverage moved significantly further north. Due to its strong earnings, Omeros Corporation procured much profits for investors. Its highly likely that the crown jewel of the pipeline (OMS-721) to deliver highly promising clinical outcomes, to gain accelerated approval, and to ultimately procure multi-blockbuster results. Last but not least, the stellar FDA due diligence to serve as industry tailwind for Atara Biotherapeutics.

Authors Notes: Were honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (IBI) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 322%, 138%, 205%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advanced and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I like to inform our readers of Seeking Alpha’s recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.

Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Atara Biotherapeutics (ATRA) SVP Sells $61,991.60 in Stock

Atara Biotherapeutics (NASDAQ:ATRA) SVP Derrell Porter sold 1,544 shares of the firm’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $40.15, for a total value of $61,991.60. Following the completion of the sale, the senior vice president now owns 12,500 shares in the company, valued at $501,875. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of ATRA traded down $2.52 during trading hours on Tuesday, reaching $39.53. 839,266 shares of the company’s stock traded hands, compared to its average volume of 905,795. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -9.88 and a beta of 2.55. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $49.90.

Get Atara Biotherapeutics alerts:

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) EPS for the quarter, meeting analysts’ consensus estimates of ($1.15). research analysts expect that Atara Biotherapeutics will post -3.58 earnings per share for the current fiscal year.

A number of research firms have issued reports on ATRA. Citigroup cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a research note on Thursday, February 15th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. JMP Securities lowered Atara Biotherapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 28th. Guggenheim began coverage on Atara Biotherapeutics in a report on Thursday, March 15th. They set a “neutral” rating on the stock. Finally, Canaccord Genuity reissued a “buy” rating and set a $70.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, March 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $42.50.

Several institutional investors and hedge funds have recently modified their holdings of the company. Pacific Heights Asset Management LLC acquired a new position in Atara Biotherapeutics during the fourth quarter worth about $453,000. Artal Group S.A. grew its holdings in Atara Biotherapeutics by 66.7% during the fourth quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock worth $18,100,000 after acquiring an additional 400,000 shares during the period. Nexthera Capital LP acquired a new position in Atara Biotherapeutics during the fourth quarter worth about $5,188,000. Bridger Management LLC grew its holdings in Atara Biotherapeutics by 57.3% during the fourth quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company’s stock worth $47,035,000 after acquiring an additional 946,086 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new position in Atara Biotherapeutics during the fourth quarter worth about $434,000. 68.73% of the stock is currently owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Top 10 Safest Stocks To Buy For 2019

 Today, I will show you how to take our very best investment ideas and make them 10 times better…   That's right. Using this simple strategy, I believe every individual investor managing less than $10 million can earn 50% a year in safe stocks. Returns at this level can transform your retirement… or even build generational wealth.   But this doesn't mean you have to buy risky stocks. And I'm not talking about anything expensive, difficult, or complex. I'm just talking about taking our best, safest ideas… and making one tiny adjustment.   It's something anyone can do. And it's easy.    Can you really make 50% a year?   Yes. In fact, it's almost certain that you will. I'm not talking about generating a little extra income. I'm talking about a way to turn our best ideas into absolute home runs. I'm talking about the best way to make a fortune in the stock market.

Top 10 Safest Stocks To Buy For 2019: Empire State Realty Trust, Inc.(ESRT)

Advisors’ Opinion:

  • [By ]

    Empire State Realty Trust (ESRT) : “The yield on this one is too low.”

    DowDuPont (DWDP) : “I’m not running away, I’m sticking with them.”

  • [By ]

    For example, nobody is going to come along and build another Empire State Building. In fact, you can actually invest in this building through the Empire State Realty Trust (NYSE: ESRT).

Top 10 Safest Stocks To Buy For 2019: Ascent Capital Group, Inc.(ASCMA)

Advisors’ Opinion:

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Both of these stocks are overlooked, undervalued, and cash flow machines. The companies are Ascent Capital Group (ASCMA) and Covanta Holdings (CVA).

  • [By Lisa Levin]

    Tuesday afternoon, the industrial sector proved to be a source of strength for the market. Leading the sector was strength from NL Industries Inc (NYSE: NL) and Ascent Capital Group Inc (NASDAQ: ASCMA).

Top 10 Safest Stocks To Buy For 2019: Virtus Investment Partners Inc.(VRTS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Virtus Investment Partners Inc (NASDAQ: VRTS) got a boost, shooting up 19 percent to $111.05 following Q3 results. Virtus Investment posted Q3 earnings of $1.64 per share on revenue of $82.3 million.

Top 10 Safest Stocks To Buy For 2019: Sears Holdings Corporation(SHLD)

Advisors’ Opinion:

  • [By Stark Merrifield]

    Sears Holdings Corp. (Nasdaq: SHLD), a company that has been around for more than 130 years, was at one time the largest mail-order retailer to rural America. In 1931 it accounted for more than 53.4% of total mail-order sales. It survived through not only one but two world wars and the Great Depression.

  • [By Paul Ausick]

    Sears Holdings Corp. (NASDAQ: SHLD).Between Sears and Kmart stores, the company plans 142 store closings, with more likely.

    Sports Authority.Another bankruptcy, with 140 stores closing.

  • [By Money Morning Staff Reports]

    Shah is keeping his eye on companies like Macy’s Inc. (NYSE: M), JCPenney Co. Inc. (NYSE: JCP), and Sears Holdings Corp. (Nasdaq: SHLD). Though these dead cats may bounce from time to time, their trajectory is decidedly downward.

Top 10 Safest Stocks To Buy For 2019: Live Nation Entertainment, Inc.(LYV)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    For his “Executive Decision” segment, Cramer checked in with Michael Rapino, president and CEO of Live Nation Entertainment (LYV) , a stock that’s up 44% since Cramer last spoke with him a little more than a year ago but also one that fell 3% in today’s session on what appeared to be solid quarterly results.

Top 10 Safest Stocks To Buy For 2019: U S Concrete, Inc.(USCR)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell 0.36 percent. Meanwhile, top losers in the sector included US Concrete Inc (NASDAQ: USCR), down 10 percent, and Commercial Metals Company (NYSE: CMC), down 4 percent.

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell 0.73 percent. Meanwhile, top losers in the sector included US Concrete Inc (NASDAQ: USCR), down 8 percent, and Seabridge Gold, Inc. (USA) (NYSE: SA), down 5 percent.

  • [By ]

    Sterling Construction Co. Inc (STRL) : “I’m going to stick with U.S. Concrete (USCR) .”

    B&G Foods (BGS) : “No, we’re going to stay away. This group is a snake pit.”

  • [By ]

    In the Lightning Round, Cramer was bullish on Goldman Sachs (GS) , Berkshire Hathaway (BRK.B) , Ecolab (ECL) , PTC (PTC) , Arista Networks (ANET) , U.S. Concrete (USCR) and Masco (MAS) .

  • [By WWW.THESTREET.COM]

    Coming up in tonight’s episode of Mad Money: Cramer interviews Bill Sandbrook, CEO of U.S. Concrete (USCR)  and focuses on opportunities for Xilinx (XLNX) .  Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

Top 10 Safest Stocks To Buy For 2019: Student Transportation Inc(STB)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Student Transportation (STB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested shorting small cap school bus transportation services stockStudent Transportation (NASDAQ: STB):

  • [By Monica Gerson]

    Student Transportation Inc (NASDAQ: STB) is estimated to post its quarterly earnings at $0.04 per share on revenue of $167.40 million.

    Exar Corporation (NYSE: EXAR) is projected to post its quarterly earnings at $0.09 per share on revenue of $38.38 million.

Top 10 Safest Stocks To Buy For 2019: Seadrill Limited(SDRL)

Advisors’ Opinion:

  • [By Paul Ausick]

    SeaDrill Ltd. (NYSE: SDRL) dropped nearly 11% Friday to post a new 52-week low of $0.41 after closing at $0.46 on Thursday. The stock’s 52-week high is $4.59. Volume of nearly about 9.4 million was less than 10% above the daily average. The company had no specific news.

  • [By Lisa Levin] Related NVCN 18 Biggest Mid-Day Losers For Wednesday Legal Overhangs Keep Ladenburg Neutral On Neovasc Despite Positive Tiara Clinical Data Boston Scientific closes Neovasc transaction (Seeking Alpha)
    Related BSX Watch These 10 Huge Call Purchases In Monday Trade Wonderful Wearables Get Their Own ETF Boston Scientific closes Neovasc transaction (Seeking Alpha) Gainers
    Neovasc Inc (US) (NASDAQ: NVCN) rose 17.3 percent to $2.65 in pre-market trading after the company reported the close of its $75 million transaction with Boston Scientific Corporation (NYSE: BSX).
    aTyr Pharma Inc (NASDAQ: LIFE) shares rose 12.3 percent to $4.10 in pre-market trading after the company disclosed 'promising' signals in myopathies with Resolaris in exploratory trials.
    Globus Maritime Ltd (NASDAQ: GLBS) shares rose 10.1 percent to $6.90 in pre-market trading after climbing 5.03 percent on Monday.
    Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares rose 9.9 percent to $3.00 in pre-market trading. Aurinia Pharmaceuticals appointed Lorin Jeffry “Jeff” Randall to its board and Chairman of the Audit Committee.
    Ocean Rig UDW Inc. (NASDAQ: ORIG) shares rose 8.7 percent to $2.89 in pre-market trading after surging 19.82 percent on Monday.
    Full House Resorts, Inc. (NASDAQ: FLL) shares rose 5.1 percent to $2.08 in pre-market trading after declining 1.98 percent on Monday.
    Seadrill Ltd (NYSE: SDRL) rose 5.1 percent to $4.13 in pre-market trading after surging 3.15 percent on Monday.
    Noble Corporation (NYSE: NE) rose 5.1 percent to $7.60 in pre-market trading after declining 5.37 percent on Monday.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 5.1 percent to $3.10 in pre-market trading. Arbutus issued additional data from its ARB-1467 Phase II
  • [By WWW.THESTREET.COM]

    Shares of Seadrill (SDRL) were gaining by 12.46% to 91 cents in pre-market trading on Tuesday morning, after the offshore drilling contract provider said its subsidiary, North Atlantic Drilling, has secured a new 10 year contract.

  • [By Dan Caplinger]

    Tuesday was another down day for the Dow Jones Industrials, which fell more than 100 points to drop further below the 20,000 level. But broader market measures were mixed, and the Nasdaq Composite even managed to gain ground. Continued uncertainty about the impact of new policies from the U.S. federal government have kept markets a bit turbulent, and the beginning of a two-day meeting of the Federal Reserve’s Open Market Committee could set the tone for monetary policy in 2017. Some stocks had bad news that sent them lower today, and among the worst performers were Seadrill (NYSE:SDRL), Roadrunner Transportation Systems (NYSE:RRTS), and Tempur Sealy International (NYSE:TPX). Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 10 Safest Stocks To Buy For 2019: Education Realty Trust Inc.(EDR)

Advisors’ Opinion:

  • [By ]

    Education Realty Trust (NYSE: EDR) is a U.S.-based REIT that specializes in owning and managing collegiate housing facilities near universities. With a market cap of $2.8 billion, this is also one of the larger REITs in the United States. EDR made four dividend payments in 2017 totaling $1.54. That gives shares a current yield of 4.3%, more than a 100% premium to the S&P 500’s 2.0%. EDR also has an impressive history of dividend hikes. Since bottoming out at $0.15 in 2008 after the financial crisis, EDR’s dividend payment has jumped 160%.

Top 10 Safest Stocks To Buy For 2019: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 5 Low Price Stocks For 2018

Dr. Kent Moors

A few years ago, in one of my books (“The Vega Factor”), I coined a phrase to explain the new way in which oil pricing was unfolding, along with the uncertainty resulting from it.

Then, the market was facing rising crude topping $100 a barrel.

Now, the situation finds oil rising into the mid-$60s after a bout of abnormally low prices.

The phenomenon described, however, applies to oil moving in either direction.

I called it “Oil Vega.”

Simply put, it refers to the increasing inability to determine the true value of crude oil based on its market price.

Now, there is a reason why I’m revisiting this phrase now.

You see, I am close to putting the finishing touch on a new investment tool that identifies stocks based on this phenomenon.

And today, I want to give you a sneak peek at one of its main components…

Top 5 Low Price Stocks For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 5 Low Price Stocks For 2018: CIENA Corporation(CIEN)

Advisors’ Opinion:

  • [By Rich Smith]

    Shares of communications equipment supplier Ciena Corporation (NYSE:CIEN) slumped more than 10% in early-morning trading on Wednesday before climbing back to “only” an 8.8% loss as of 3:15 p.m. EST.

  • [By Trey Thoelcke]

    Ciena Corp. (NYSE: CIEN) will report its most recent quarterly results Thursday morning. The consensus estimates call for EPS of $0.49 and $726.84 million in revenue. Shares closed at $23.87 on Friday, in a 52-week range of $18.94 to $27.98. The consensus price target is $30.77.

  • [By WWW.THESTREET.COM]

    Earnings of note in the coming week include Analogic (ALOG) and Ascena Retail (ASNA) on Monday; Bojangles (BOJA) , H&R Block (HRB) , and Dick’s Sporting Goods (DKS) , Michaels (MIK) , and Urban Outfitters (URBN) on Tuesday; Ciena (CIEN) , Bankrate (RATE) , Express (EXPR) , Vera Bradley (VRA) , and Bob Evans Farms (BOBE) on Wednesday; El Pollo Loco (LOCO) , Hugo Boss (BOSSY) , Party City (PRTY) , Signet Jewelers (SIG) , and Verifone Systems (PAY) on Thursday; and Kirkland’s (KIRK) , and Vail Resorts (MTN) on Friday.

  • [By Lee Jackson]

    Ciena Corp. (NYSE: CIEN) is another tech company that saw insider selling last week. The president and CEO of the optical giant, Gary Smith, sold a reported 114,318 shares at $24.67 per share. The total for the trade was set at a solid $2,820,225. Shares closed last Friday at $24.41, in a 52-week range of $15.62 to $25.19. The consensus price target is $28.36.

  • [By Billy Duberstein]

    The reasons for the price drop could be a number of things, including increased competition, notably from Ciena(NYSE: CIEN). This was noted by CEO Thomas Fallon who, in the recent conference call, noted competitors may be trying to “buy” market share:

Top 5 Low Price Stocks For 2018: Cameco Corporation(CCJ)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, the Athabasca Basin is home to the McArthur River Uranium Mine -the worlds largest high-grade uranium deposit(accounting for 13% of world mine production) operated by mid cap uranium producer Cameco Corp (NYSE: CCJ).

  • [By Jim Robertson]

    Uranium was first discovered in the region in the 1940s with the first mine being the Rabbit Lake Mine which was discovered in 1968 by Gulf Mineral Resources and opened in 1975. The most important current mineisCameco Corps (NYSE: CCJ) McArthur River mine which isthe world’s largest high-grade uranium mine producing some 13% of global uranium production. Other important Athabasca Basin uranium mines include the Cigar Lake Mine, the Cluff Lake mine (now closed), the Key Lake mine and the McClean Lake mine plus the region continues to be an important center for uranium exploration for good reason as the following infographic illustrates:

Top 5 Low Price Stocks For 2018: W&T Offshore Inc.(WTI)

Advisors’ Opinion:

  • [By Lee Jackson]

    W&T Offshore Inc. (NYSE: WTI) had a big buy hit the tape last week. CEO Tracy Krohn picked up a massive 1,180,888 shares of the independent oil and natural gas producer at $1.94 per share. The total for the trade came in right at the $2 million level.The company engages in the acquisition, exploration and development of oil and natural gas properties in the Gulf of Mexico. The stock closed Friday at $2.67, so outstanding timing, indeed.

  • [By Lisa Levin]

    On Wednesday, the energy sector proved to be a source of strength for the market. Leading the sector was strength from SM Energy Co (NYSE: SM) and W&T Offshore, Inc. (NYSE: WTI).

  • [By John Bromels]

    Shares of oil and gas drillerW&T Offshore(NYSE:WTI) fell throughout April, finishing the month at $2.04 per share, down 26.4%.

    W&T is a small company primarily focused on natural gas liquids production in the Gulf of Mexico. In April, its market cap dropped about $100 million to $280 million. Huge swings like that aren’t uncommon for small companies, but what was unusual was the apparent lack of rationale for the drop.

Top 5 Low Price Stocks For 2018: Time Warner Inc.(TWX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    That’s old-fashioned TV mated with born-again 2017 e-commerce. And then the almost-circular question of where that aging behemoth — television — may fit in. It’s the same digital/TV puzzle being worked at Comcast’s (CMCSA) NBCUniversal, with its BuzzFeed/Vox investments, and at Time Warner’s (TWX) Turner through its Mashable investment.

  • [By WWW.THESTREET.COM]

    In early 2018, Viacom plans to change the name of Spike to the Paramount Network to better link its film studio with its cable TV business and expand its programming to reach a wider audience, something that Time Warner (TWX) has done over the past two years with TNT and TBS. Bakish also said that half of Paramount’s film slate would originate from Viacom’s television properties.

  • [By Matthew Briar]

    The phrase “over the top television” or “OTT” for short, aren’t exactly new terms. The phrase/abbreviation was coined shortly after Netflix, Inc. (NASDAQ:NFLX) became a viable alternative to traditional cable television subscriptions a little less than a decade ago. The over-the-top battle didn’t get heated, though, until the past few months. But, now that some more gladiators are in the arena, sparks are starting to fly.

    They’re still flying too, and should do so for a while if a small startup called Viva Entertainment Group Inc (OTCMKTS:OTTV) has anything to do with it it. See, while Netflix, Hulu — jointly owned by Time Warner, Walt Disney Co (NYSE:DIS) and Twenty-First Century Fox Inc (NASDAQ:FOXA) — and a whole slew of other new players in this market may want to take notice of this up-and-comer. At the same time, investors may want to take a step back and look at where the real money in the OTT business is going to be made over the course of the next several years. OTTV plays a prominent role in that picture.

    Contrary to popular belief, Netflix isn’t the dominant name it used to be in the Internet-delivered television industry. Yes, it was the first on the scene as such was was able to carve out the biggest piece of the market. It’s largely become a commoditized business in the meantime though.

    For example, outside of Hulu and Netflix, CBS Corporation (NYSE:CBS) has jumped into the fray with a service called CBS All Access. The product allows subscribers -for a nominal monthly fee – access a variety of CBS programming via the Internet. HBO, from Time Warner Inc (NYSE:TWX), has found some measurable success with its subscription-based Internet television service called HBO Go.

    Sling TV, from DISH Network Corp (NASDAQ:DISH), is another one of the alternatives to the alternative that’s truly made a dent in the over the top market…. by aggregating a variety of television channels into an entire package and then selling that p

  • [By Matthew Briar]

    The phrase “over the top television” – or its acronym “OTT” – aren’t necessarily newly-coined ones. The phrase/abbreviation materialized shortly after Netflix, Inc. (NASDAQ:NFLX) became a viable alternative to traditional cable television services less than a decade ago. The over-the-top race didn’t really heat up, however, until the past few months. Once it did heat up though, sparks started to fly in earnest.

    They’re still flying too, and will be for a while if a small startup called Viva Entertainment Group Inc (OTCMKTS:OTTV) has anything to say about it. Netflix, Hulu [jointly owned by Walt Disney Co (NYSE:DIS) and Twenty-First Century Fox Inc (NASDAQ:FOXA)] and all the rest of the relatively new players in this space may want to look over their shoulder. In the meantime, investors may want to take a step back and look at where the real money in the OTT industry is going to be made during the next 10 years. OTTV plays a prominent role in that picture.

    Contrary to popular belief, Netflix isn’t the totally dominant name it used to be in the Internet-delivered television industry. It was admittedly the first on the scene, and therefore was able to carve out the biggest piece of the market (which it still holds to this day). It’s largely become a commoditized business though.

    Case in point? Aside from Hulu and Netflix, CBS Corporation (NYSE:CBS) has jumped into the game with its product called CBS All Access. The service allows subscribers, for a nominal monthly fee, to access a variety of CBS programming via the Internet. HBO, from Time Warner Inc (NYSE:TWX), has found respectable success with its subscription-based Internet television service called HBO Go.

    Sling TV, from DISH Network Corp (NASDAQ:DISH), has really broken new ground in the over the top market by aggregating a variety of television channels into an entire package and then selling that package at a rate that’s much less than what it would cost a cable subscriber

  • [By Keith Noonan]

    Time Warner (NYSE:TWX) has signed Avengers series director Joss Whedon to make a Batgirl movie that’s part of its DC Extended Universe (DCEU) movie franchise. In addition to television series including Buffy: The Vampire Slayer and Firefly, Whedon is known for writing and directing Disney’s (NYSE:DIS) first two Avengers films, so the director’s move to the DCEU franchise presents a notable creative shakeup in the cinematic superhero competition.